Rotterdam, Netherlands
Rotterdam, Netherlands

Time filter

Source Type

Schmid A.,Wilhelminenspital | Singer E.,Hospital Pharmacy | Chott A.,Wilhelminenspital
Antimicrobial Agents and Chemotherapy | Year: 2014

Clostridium difficile infections (CDI) in hospitalized patients are known to be closely related to antibiotic exposure. Although several substances can cause CDI, the risk differs between individual agents. In Vienna and other eastern parts of Austria, CDI ribotype 027 is currently highly prevalent. This ribotype has the characteristic of intrinsic moxifloxacin resistance. Therefore, we hypothesized that moxifloxacin restriction can decrease the number of CDI cases in hospitalized patients. Our antibiotic stewardship (ABS) group applied an information campaign on CDI and formal restriction of moxifloxacin in Wilhelminenspital (Vienna, Austria), a 1,000- bed tertiary care hospital. The preintervention period (period 1) was January through May 2013, and the intervention period (period 2) was June through December 2013. We recorded the defined daily doses (DDD) of moxifloxacin and the number of CDI patients/month. Moxifloxacin use was reduced from a mean (± standard error of the mean [SEM]) of 1,038 ± 109 DDD per month (period 1) to 42 ± 10 DDD per month (period 2) (P = 0.0045). Total antibiotic use was not affected. The mean (±SEM) numbers of CDI cases in period 1 were 59 ± 3 per month and in period 2 were 32 ± 3 per month (46% reduction; P = 0.0044). Reducing moxifloxacin use in combination with providing structured information on CDI was associated with an immediate decrease in CDI rates in this large community teaching hospital. Copyright © 2014, American Society for Microbiology. All Rights Reserved.


— This report studies sales (consumption) of Clinical Information System in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Clinical Information System in these regions, from 2011 to 2021 (forecast), like Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Cloud Based Web Based Split by applications, this report focuses on sales, market share and growth rate of Clinical Information System in each application, can be divided into Hospital Pharmacy Laboratory Global Clinical Information System Sales Market Report 2017 1 Clinical Information System Overview 1.1 Product Overview and Scope of Clinical Information System 1.2 Classification of Clinical Information System 1.2.1 Cloud Based 1.2.2 Web Based 1.3 Application of Clinical Information System 1.3.1 Hospital 1.3.2 Pharmacy 1.3.3 Laboratory 1.4 Clinical Information System Market by Regions 1.4.1 United States Status and Prospect (2012-2022) 1.4.2 China Status and Prospect (2012-2022) 1.4.3 Europe Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value and Volume) of Clinical Information System (2012-2022) 1.5.1 Global Clinical Information System Sales and Growth Rate (2012-2022) 1.5.2 Global Clinical Information System Revenue and Growth Rate (2012-2022) 9 Global Clinical Information System Manufacturers Analysis 9.1 Clinicmaster 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Clinical Information System Product Type, Application and Specification 9.1.2.1 Cloud Based 9.1.2.2 Web Based 9.1.3 Clinicmaster Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Quintiles 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Clinical Information System Product Type, Application and Specification 9.2.2.1 Cloud Based 9.2.2.2 Web Based 9.2.3 Quintiles Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Accenture 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Clinical Information System Product Type, Application and Specification 9.3.2.1 Cloud Based 9.3.2.2 Web Based 9.3.3 Accenture Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Allegro CTMS 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Clinical Information System Product Type, Application and Specification 9.4.2.1 Cloud Based 9.4.2.2 Web Based 9.4.3 Allegro CTMS Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.4.4 Main Business/Business Overview 9.5 iMDsoft 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Clinical Information System Product Type, Application and Specification 9.5.2.1 Cloud Based 9.5.2.2 Web Based 9.5.3 iMDsoft Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.5.4 Main Business/Business Overview 9.6 Surgical Information Systems 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Clinical Information System Product Type, Application and Specification 9.6.2.1 Cloud Based 9.6.2.2 Web Based 9.6.3 Surgical Information Systems Clinical Information System Sales, Revenue, Price and Gross Margin (2012-2017) 9.6.4 Main Business/Business Overview For more information, please visit https://www.wiseguyreports.com/sample-request/928007-global-clinical-information-system-sales-market-report-2017


News Article | November 10, 2016
Site: www.PR.com

Global Drug Delivery Devices Market, By Product Type (Oral Solid, Liquid, Semi-Solid), Injectable, Topical, Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tenders, Online Pharmacy), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa, Rest of the World) – Trends and Forecast to 2022 Dallas, TX, November 10, 2016 --( Request for sample pages: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/ On the basis of product type the global drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drugs are further sub segmented into solid drug, semi-solid drug and liquid drug. The Pulmonary drug delivery segment is further sub segmented into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. Topical drug delivery segment is further sub segmented based on form into liquid, semi-solid, solid and transdermal. Based on the distribution channel the market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy. On the basis of end-users the global drug delivery devices market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others. Based on geography the market is segmented into North America, Europe, Asia-Pacific, South America and rest of the world. The report of this market shares countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa. The report includes market shares of global drug delivery devices market for North America, Europe and Asia Pacific. Read more: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/ The key players operating in this market are Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Dallas, TX, November 10, 2016 --( PR.com )-- The Global Drug Delivery Devices Market is segmented on the basis of product type, distribution channel, end-user and geography.Request for sample pages: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/On the basis of product type the global drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal. Oral drugs are further sub segmented into solid drug, semi-solid drug and liquid drug. The Pulmonary drug delivery segment is further sub segmented into metered dose inhalers (MDI), dry powder inhalers (DPI) and nebulizers. Topical drug delivery segment is further sub segmented based on form into liquid, semi-solid, solid and transdermal.Based on the distribution channel the market is segmented into hospital pharmacies, pharmacy stores, direct tenders and online pharmacy.On the basis of end-users the global drug delivery devices market is segmented into hospitals, over the counter, clinics, home healthcare, community healthcare, and others.Based on geography the market is segmented into North America, Europe, Asia-Pacific, South America and rest of the world. The report of this market shares countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa. The report includes market shares of global drug delivery devices market for North America, Europe and Asia Pacific.Read more: http://databridgemarketresearch.com/reports/global-drug-delivery-devices-market/The key players operating in this market are Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others.About Data Bridge Market Research:Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Click here to view the list of recent Press Releases from Data Bridge Market Research


Wildschut E.D.,Sophia Childrens Hospital | Ahsman M.J.,Hospital Pharmacy | Allegaert K.,University Hospitals | Mathot R.A.A.,Hospital Pharmacy | Tibboel D.,Sophia Childrens Hospital
Intensive Care Medicine | Year: 2010

Purpose: The aim of this in vitro study was to evaluate potential determinants of drug loss in different ECMO circuits. Methods: Midazolam, morphine, fentanyl, paracetamol, cefazolin, meropenem and vancomycin were injected into three neonatal roller pump, two paediatric roller pump and two clinically used neonatal roller pump circuits, all with a silicone membrane, and two neonatal centrifugal pump circuits with polypropylene hollow-fibre membranes. Serial blood samples were taken from a post-oxygenator site. Drug recovery was calculated as the ratio between the determined and the theoretical maximum concentration. The latter was obtained by dividing dose by theoretical circuit volume. Results: Average drug recoveries at 180 min in three neonatal silicone membrane roller pump circuits were midazolam 0.62%, morphine 23.9%, fentanyl 0.35%, paracetamol 34.0%, cefazolin 84.3%, meropenem 82.9% and vancomycin 67.8%. There was a significant correlation between the lipophilicity of the drug expressed as log P and the extent of drug absorption, p < 0.001. The recovery of midazolam and fentanyl in centrifugal pump circuits with hollow-fibre membrane oxygenator was significantly higher compared to neonatal roller pump circuits with silicone membranes: midazolam 63.4 versus 0.62%, fentanyl 33.8 versus 0.35%, p < 0.001. Oxygenator size and used circuits do not significantly affect drug losses. Conclusions: Significant absorption of drugs occurs in the ECMO circuit, correlating with increased lipophilicity of the drug. Centrifugal pump circuits with hollow-fibre membrane oxygenators show less absorption for all drugs, most pronounced for lipophilic drugs. These results suggest that pharmacokinetics and hence optimal doses of these drugs may be altered during ECMO.


Minguez-Sanz M.-P.,University of Valencia | Salort-Llorca C.,Hospital Pharmacy | Silvestre-Donat F.-J.,University of Valencia
Medicina Oral, Patologia Oral y Cirugia Bucal | Year: 2011

Introduction: Burning mouth syndrome (BMS) is characterized by an oral burning sensation in the absence of any organic disorders of the oral cavity. Although the cause of BMS is not known, a complex association of biological and psychological factors has been identified, suggesting the existence of a multifactorial etiology. Material and Method: A PubMed/Medline search was used to identify articles describing the different hypotheses regarding the etiology of BMS, as well as the psychological and anatomical data upon which such hypotheses are fundamented. Results: A review and update was made of the different hypotheses relating to the etiology of BMS (psychogenic factors, hormone disorders, neuropathic alterations, oral phantom pain, neuroplasticity and neuroinflammation), with a view to globally establishing possible relationships among them. Conclusions: In-depth investigation is needed to clarify the etiopathogenic mechanisms of BMS and its triggering factors, in order to develop effective and individualized management strategies that can be extended to patients in each different BMS subgroup. © Medicina Oral.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Radiodermititis Market: By Product type (Topical, Oral Medication and Dressings), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy Store, and Online Store) & By Region-Forecast (2016-2021)" report to their offering. This report identifies the global radiodermititis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global radiodermititis market. Geographically Asia-Pacific dominated radiodermititis market driven by best in the developing healthcare infrastructure, increasing awareness, increasing cancer patients and growing spending by the citizens towards healthcare expenditure. Asia-Pacific was followed by Europe and North America as second and third largest market for radiodermititis market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region. Some of the major companies' profiles in detail are as follows: For more information about this report visit http://www.researchandmarkets.com/research/lc94vg/radiodermititis


Borras-Blasco J.,Hospital Pharmacy | Gracia-Perez A.,Hospital Of Sagunto | Rosique-Robles J.D.,Hospital Pharmacy | Castera M.E.,Hospital Pharmacy | Abad F.J.,Hospital Pharmacy
Expert Opinion on Biological Therapy | Year: 2014

Objective: To determine the clinical and economic impact of etanercept 25 mg/week (ETN25) on rheumatoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) patients in sustained clinical remission. Methods: Observational, retrospective cohort of patients treated with etanercept 50 mg/week (ETN50) who achieved and maintained clinical remission (Disease Activity Score 28 < 2.6 or BASDAI < 2) over a period of 1 year and had slow worsening of structural changes were enrolled in an off-label program (January 2006 to June 2013) to switch from ETN50 to ETN25. Economic impact was assessed using Enbrel® official prices for Spain. Results: From 1 January 2006 to 1 June 2013, 98 RA, 40 PA and 47 AS patients were treated with ETN50; 39 (24%) patients (20 women; age = 53 ± 7 years; 24 RA, 7 PA, 8 AS) received ETN25 for at least 0.5 years (2.6 ± 2.0 years; range = 0.5-7.3 years). As of 1 June 2013, 29 (74%) patients continued on ETN25. RA patients: 17 patients continued on ETN25, 5 patients discontinued use due to reactivation of RA (4 switched back to ETN50 and 1 switched to adalimumab; all regained clinical remission) and 2 patients discontinued use due to adverse reactions. PA patients: four patients continued on ETN25, two patients discontinued use due to reactivation of PA (switched back to ETN50, regaining clinical remission) and one patient discontinued use due to adverse reaction. All AS patients continued on ETN25. The total savings associated with ETN25 over the 7-year observation period were 622,073, resulting in the ability to treat 52 additional patients with ETN50 for one year without increasing total ETN costs. Conclusion: ETN25 produces cost savings while maintaining clinical response in a high proportion of patients after at least one year under clinical remission with ETN50. At a time when the cost of therapy is an unavoidable component of healthcare treatment decisions, ETN25 could be a cost-effective option for selective RA, PA and AS patients. © 2014 Informa UK, Ltd.


Hesselink D.A.,Erasmus University Rotterdam | Bouamar R.,Hospital Pharmacy | Van Gelder T.,Erasmus University Rotterdam | Van Gelder T.,Hospital Pharmacy
Therapeutic Drug Monitoring | Year: 2010

Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use of cyclosporine and tacrolimus and has been observed after all types of transplantation, as well as during treatment of autoimmune disease. Extensive alterations in the renal architecture including glomerular sclerosis, tubular atrophy and interstitial fibrosis may lead to end-stage renal failure. Increasing evidence shows that pharmacogenetic factors explain part of the between-patient differences in susceptibility to developing CNI-induced nephrotoxicity. In this paper this evidence is reviewed, with special emphasis on the role of genetic factors influencing metabolism and transportation of CNIs in both acceptor and donor. © 2010 by Lippincott Williams & Wilkins.


Tartarone A.,Centro Of Riferimento Oncologico Della Basilicata | Lerose R.,Hospital Pharmacy
Therapeutic Advances in Respiratory Disease | Year: 2015

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs. © The Author(s), 2015.


Tartarone A.,Centro Of Riferimento Oncologico Della Basilicata | Lerose R.,Hospital Pharmacy
Therapeutic Drug Monitoring | Year: 2010

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare but severe cutaneous adverse reactions related to a variety of medications. Although rare, SJS and TEN have a significant impact on public health because of high mortality. Also, if the SJS/TEN physiopathology is still unclear, a specific immune response to one or more drugs is involved, constituting a form of delayed-type hypersensitivity. Patients with SJS/TEN are often critically ill; therefore, they must be admitted to hospitals capable of delivering critical care. Currently, no treatment modality has been established as standard for these patients; therefore, therapy is primarily supportive and symptomatic and involves a multidisciplinary approach. © 2010 by Lippincott Williams & Wilkins.

Loading Hospital Pharmacy collaborators
Loading Hospital Pharmacy collaborators